Parthenon Therapeutics
Mace Rothenberg is currently a Scientific Advisor at Parthenon Therapeutics. Prior to this, they were with Aulos Bioscience, Tango Therapeutics, and Pfizer. Mace has also been a Professor of Medicine and Ingram Professor of Cancer Research, as well as an Executive Officer and Assistant/Associate Professor of Medicine at Vanderbilt University Medical Center and the University of Texas Health Science Center at San Antonio. Mace began their career in 1988 as an Assistant to the Director at the National Cancer Institute (NCI).
Dr. Mace Rothenberg attended the Horace Mann School for their BA, where they graduated with honors in art. Mace then went on to New York University for their Doctor of Medicine - MD. After finishing medical school, they completed a residency in internal medicine at Vanderbilt University. Finally, they did a fellowship in medical oncology at the National Cancer Institute (NCI). Mace is certified from the American Board of Internal Medicine and is board certified in both internal medicine and medical oncology.
This person is not in the org chart
This person is not in any offices
Parthenon Therapeutics
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on rigorous, groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time.